Biotech entity
All 1 tracked stories fall under one category: clinical-trial. VLA15 is most often covered alongside FDA, which appears in 1 of these 1 story. VLA15 appears in 1 tracked Biotech story from March 25, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. VLA15 is most often covered alongside FDA, which appears in 1 of these 1 story. VLA15 appears in 1 tracked Biotech story from March 25, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering VLA15. Shared-story counts are live from our verified record — not editorial picks.
Potential Launch
Anticipated commercial availability following regulatory approval and CDC recommendation.
Regulatory Filing
Expected submission of Biologics License Application (BLA) to the FDA.
Efficacy Results
Trial data shows over 70% efficacy against Lyme disease in endemic regions.
Phase 3 Initiation
Pfizer and Valneva launch the VALOR Phase 3 clinical trial for VLA15.
Pfizer and Valneva have reported positive Phase 3 results for their Lyme disease vaccine candidate, VLA15, demonstrating an efficacy rate exceeding 70%. This development marks a significant milestone in addressing the growing public health threat of tick-borne illnesses, potentially offering the first preventative vaccine for the disease in over two decades.
VLA15 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
